Greenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Buys $12,910.00 in Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Jaye Thompson acquired 1,000 shares of the company’s stock in a transaction dated Thursday, November 21st. The shares were acquired at an average cost of $12.91 per share, with a total value of $12,910.00. Following the completion of the purchase, the vice president now owns 264,148 shares in the company, valued at approximately $3,410,150.68. This represents a 0.38 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Greenwich LifeSciences Price Performance

Greenwich LifeSciences stock opened at $14.57 on Thursday. The company has a market cap of $191.60 million, a price-to-earnings ratio of -18.21 and a beta of 1.62. Greenwich LifeSciences, Inc. has a 12 month low of $8.00 and a 12 month high of $21.44. The stock’s 50-day moving average is $13.81 and its 200-day moving average is $14.44.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright raised their price target on Greenwich LifeSciences from $36.00 to $38.00 and gave the stock a “buy” rating in a research report on Friday, August 23rd.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Rhumbline Advisers acquired a new position in shares of Greenwich LifeSciences during the 2nd quarter valued at $117,000. Barclays PLC boosted its position in shares of Greenwich LifeSciences by 323.3% in the third quarter. Barclays PLC now owns 8,560 shares of the company’s stock worth $123,000 after buying an additional 6,538 shares during the period. Garden State Investment Advisory Services LLC purchased a new stake in shares of Greenwich LifeSciences during the 3rd quarter valued at about $253,000. Bank of New York Mellon Corp acquired a new position in Greenwich LifeSciences during the 2nd quarter worth approximately $264,000. Finally, State Street Corp grew its position in Greenwich LifeSciences by 4.4% in the third quarter. State Street Corp now owns 71,408 shares of the company’s stock valued at $1,026,000 after acquiring an additional 3,005 shares in the last quarter. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.